Brief: Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219
29/02/2024 14:14
Feb 29 (Reuters) - Atara Biotherapeutics Inc ATRA.O :
* ATARA BIOTHERAPEUTICS RECEIVES FDA CLEARANCE OF IND
APPLICATION
IN LUPUS NEPHRITIS FOR ATA3219, AN ALLOGENEIC CAR T THERAPY
* ATARA BIOTHERAPEUTICS INC - INITIAL CLINICAL DATA IN NHL
ANTICIPATED IN H2 2024 AND FOR LUPUS NEPHRITIS IN H1 2025
Source text for Eikon: ID:nBw804y2sa
Further company coverage: ATRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atara Biotherapeutics
See all newsBrief: Atara Biotherapeutics - May Offer Up To $79.27 Million In Common Stock As Of May 12, 2026 - SEC Filing
Atara Biotherapeutics Q1 revenue drops after prior-year one-time gain
Brief: Atara Biotherapeutics Q1 EPS USD -0.29
NASDAQ RESUMED AT 03:40 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:30 PM